Aims To define the pathways involved in tumour formation, and to target these pathways with novel, preclinical agents. Objectives: 1) To identify pathways in cylindroma formation by: a) Gene expression profiling of human cylindroma tissue, to identify the key regulatory pathways, abrogation of which are associated with tumourigenesis. b) To confirm the gene expression microarray results by secondary techniques, namely, immunohistochemistry, quantitative PCR and Western blot analysis. 2) The development of a primary cylindroma cell line: a) To allow the investigation of biological functions of novel therapeutically relevant pathways, as highlighted by the array data. b) To be the basis of a drug-screening assay to test preclinical agents that target the abrogated pathways defined above. The ultimate goal will be to begin clinical trials of non-surgical treatments in FC, to improve quality of life, prognosis, and outcome.